37S Stock Overview
Engages in the design, manufacture, and marketing of implants and surgical instruments for treating disorder of spinal column.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Spineway SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.59 |
| 52 Week High | €944.00 |
| 52 Week Low | €0.48 |
| Beta | 1.31 |
| 11 Month Change | -32.04% |
| 3 Month Change | -54.66% |
| 1 Year Change | -99.92% |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 37S | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -6.0% | -3.5% | 0.8% |
| 1Y | -99.9% | 2.2% | 6.1% |
Return vs Industry: 37S underperformed the German Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: 37S underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| 37S volatility | |
|---|---|
| 37S Average Weekly Movement | 32.5% |
| Medical Equipment Industry Average Movement | 4.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 37S's share price has been volatile over the past 3 months.
Volatility Over Time: 37S's weekly volatility has decreased from 86% to 33% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 54 | Stephane Le Roux | www.spineway.com |
Spineway SA engages in the design, manufacture, and marketing of implants and surgical instruments for treating disorder of spinal column. The company offers ayers rock, an anterior cervical interbody fusion cage; blue mountain, an anterior cervical interbody fusion plate; mont blanc, a posterior thoracolumbar pedicle screws; mont blanc baby, a pediatric growing rod system; mont blanc 3d+, a coplanar alignment system; posterior osteosynthesis systems; kili, an anterior lumbar interbody fusion cage; twin peaks plif posterior lumbar interbody fusion cages; twin peaks tlif transforaminal lumbar interbody fusion cages; and mont blanc mis, a mini-invasive thoracolumbar system. It also provides neve, a biomaterial bone substitute for bone regeneration; and cervical and lumbar prosthesis elastic spine pads.
Spineway SA Fundamentals Summary
| 37S fundamental statistics | |
|---|---|
| Market cap | €499.78k |
| Earnings (TTM) | -€6.51m |
| Revenue (TTM) | €11.36m |
0.0x
P/S Ratio-0.1x
P/E RatioIs 37S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 37S income statement (TTM) | |
|---|---|
| Revenue | €11.36m |
| Cost of Revenue | €8.89m |
| Gross Profit | €2.46m |
| Other Expenses | €8.97m |
| Earnings | -€6.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.82 |
| Gross Margin | 21.69% |
| Net Profit Margin | -57.32% |
| Debt/Equity Ratio | 13.5% |
How did 37S perform over the long term?
See historical performance and comparison